Thema: Fotemustin in der Glioblastomtherapie?
Fotemustin in der Glioblastomtherapie?
Linus[a]
23.01.2006 12:57:00
Kennt jemand den folgenden Artikel von 2003. Was ist davon zu halten?
Warum wird Fotemustine nicht in Deutschland eingesetzt?
Br J Cancer. 2003 Feb 24;88(4):496-501
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.
Fazeny-Dorner B, Veitl M, Wenzel C, Rossler K, Ungersbock K, Dieckmann K, Piribauer M, Hainfellner J, Marosi C.
Clinical Division of Oncology and Ludwig Boltzmann Institute for Clinical and Experimental Oncology, Department of Internal Medicine I, University of Vienna, Austria. barbara.doemer@chello.at
A total of 55 patients with histologically proven glioblastoma multiforme (total gross resection: n=24, subtotal resection: n=20, stereotactic biopsy: n=11) were treated with the combination of dacarbazine (D) (200 mg m(-2)) and fotemustine (F) (100 mg m(-2)) and concomitant radiotherapy (2 Gy day(-1), 5 days per week using limited fields up to 60 Gy) to assess efficacy and toxicity of this regimen. Survival (median survival, 12-, 18- and 24-month survival rates) and time to progression (median time to progression (TTP), 6-month progression-free survival) were analysed by Kaplan-Meier´s method. A total of 268 (range 1-8, median: 5) cycles were administered. Median survival is 14.5+ (range: 0.5-40+) months, and the 12-, 18- and 24-month survival rates are 58, 29 and 23%, respectively. Median TTP from the start of D/F therapy is 9.5+ (range: 0.5-33+) months. The 6-month progression-free survival is 54%. Partial remissions were observed in 3.6%. Main toxicity was thrombocytopenia. Five patients were excluded from further D/F application, four patients because of prolonged thrombocytopenia NCI-CTC grades 3 and 4 and one patient because of whole body erythrodermia. One patient died because of septic fever during thrombocytopenia and leukopenia NCI-CTC grade 4 after the first cycle. No other toxicities of NCI-CTC grade 3 or 4 occurred. The treatment is feasible in a complete outpatient setting and the results of the D/F regimen justify further investigations with these compounds.
Warum wird Fotemustine nicht in Deutschland eingesetzt?
Br J Cancer. 2003 Feb 24;88(4):496-501
Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.
Fazeny-Dorner B, Veitl M, Wenzel C, Rossler K, Ungersbock K, Dieckmann K, Piribauer M, Hainfellner J, Marosi C.
Clinical Division of Oncology and Ludwig Boltzmann Institute for Clinical and Experimental Oncology, Department of Internal Medicine I, University of Vienna, Austria. barbara.doemer@chello.at
A total of 55 patients with histologically proven glioblastoma multiforme (total gross resection: n=24, subtotal resection: n=20, stereotactic biopsy: n=11) were treated with the combination of dacarbazine (D) (200 mg m(-2)) and fotemustine (F) (100 mg m(-2)) and concomitant radiotherapy (2 Gy day(-1), 5 days per week using limited fields up to 60 Gy) to assess efficacy and toxicity of this regimen. Survival (median survival, 12-, 18- and 24-month survival rates) and time to progression (median time to progression (TTP), 6-month progression-free survival) were analysed by Kaplan-Meier´s method. A total of 268 (range 1-8, median: 5) cycles were administered. Median survival is 14.5+ (range: 0.5-40+) months, and the 12-, 18- and 24-month survival rates are 58, 29 and 23%, respectively. Median TTP from the start of D/F therapy is 9.5+ (range: 0.5-33+) months. The 6-month progression-free survival is 54%. Partial remissions were observed in 3.6%. Main toxicity was thrombocytopenia. Five patients were excluded from further D/F application, four patients because of prolonged thrombocytopenia NCI-CTC grades 3 and 4 and one patient because of whole body erythrodermia. One patient died because of septic fever during thrombocytopenia and leukopenia NCI-CTC grade 4 after the first cycle. No other toxicities of NCI-CTC grade 3 or 4 occurred. The treatment is feasible in a complete outpatient setting and the results of the D/F regimen justify further investigations with these compounds.
Linus[a]
PD DR. Mursch
24.01.2006 18:04:06
Die Zahl der untersuchten Patienten ist nicht besonders groß. Die Therapie hat keinen sichern Vorteil z.B. gegenüber Temozolomid.
PD DR. Mursch